Robert R . Recker, MD

Department

Medicine

Position

Professor Emeritus

Presentations

• Kimmel, DB, Desyatova, A, Lappe, JM, Vennin, S, Turner, JA, Akhter, MP, Recker, RR. Cortical Thickness and Bone Material Properties are Related to Fragility Fracture in Post-Menopausal Women With Normal Bone Mineral Density. Plenary poster presentation at the ASBMR 2021 Annual Meeting, San Diego, CA, October 1-4, 2021 2021
• Akhter, MP, Bare, SP, Armas, LA, Lappe, JM, Recker, RR. Bone Structure and Lacunar Void Properties in Diabetic Postmenopausal Women. Poster presentation at the ASBMR 2021 Annual Meeting, San Diego, CA, October 1-4, 2021. 2021
• Disuse alters the size of osteocyte lacunar voids. Recker, RR. ASBMR 2018, Montreal, Canada. 2018
• McDonald D, Hugenroth B, Rosauer B, Recker R, Akhter M. Quantifying microdamage in fatigue loaded cortical bone tissue. ASBMR 2017 Annual Meeting, Denver, CO 2017
• 1. Cohen A, Demster DW, Zhou H, Recker RR, Lappe JM, Kamanda-Kosseh M, Bucovsky M, RoyChoudhury A, Stubby J, Stein EM, Nickolas TL, Shane E. Quadruple-labeled trans-iliac crest biopsies quantify bone formation response to teriparatide in premenopausal women with idiopathic osteoporosis. ASBMR 2017 Annual Meeting, Denver, CO 2017
• Dempster D, Zhou H, Recker R, Brown J, Recknor C, Lewiecki M, Miller P, Rao S, Kendler D, Lindsay R, Krege J, Alam J, Taylor K, Ruff V. Modeling- and Remodeling-Based Bone Formation in the Anabolic Versus Antiresorptive (AVA) Study in Postmenopausla Women with Osteoporosis. Poster presented at the World Congress Osteoprosis, Osteoarthritis, & Musculoskeletal Disease, Florence, Italy March 23-26, 2017 2017
• Addosi N, George A, Recker R, Anderson R. Clinical Features of two patients with rebound-associated vertebral fractures after Denosumab discontinuation. Creighton University Endocrine presentation 2017
• Lappe, J., Travers-Gustafson, D., Garland, C., Heaney, R., Recker, R., and Watson, P. Vitamin D3 and calcium supplementation significantly decreases cancer risk in older women. Oral presentation presented as a late-breaking abstract at the American Public Health Association Annual meeting , Denver, CO, October 29 November 2, 2016 2016
• Singh S, Recker R. Curious case of Cretinism and Resistance to Thyroid Hormone(RTH): Is the Cretinism result of misdiagnosis or due to mutation itself? Poster presented at the 86th Annual Meeting of the ATA in Denver, Colorado from September 21 - 25, 2016 2016
• Dempster D, Zhou H, Recker R, Brown J, Recknor C, Lewiecki E, Miller P, Rao S, Kendler D, Lindsay R, John K, Alam J, Taylor K, Ruff V. Longitudinal Changes in Modeling-and Remodeling-Based Bone Formation with an Anabolic vs. an Antiresorptive Agent in the AVA Osteoporosis Study. Oral presentation at the ASBMR 2016 Annual Meeting, Atlanta, GA, September 16-19, 2016 2016
• Greenspan S, Singer A, Recker R, Lee D, Karp S, Marchand B, Zeldow D, Stern L. A Demonstration Study of the Fracture Liaison Service (FLS) Model of Care for Patients with Osteoporotic Fractures. Poster Presented at the ASBMR 2016 Annual Meeting, Atlanta, GA, September 16-19, 2016. 2016
• Recker R, Dempster D, Langdahl B, Ellis G, de Villiers T, Cohn D, Doleckyj S, Giezek H, Santora A, Duong L. Effects of Odanacatib on Transilial Cortical Remodeling/Modeling and Microarchitecture in Postmenopausal Women with Osteoporosis: 5-Year Data from the Extension of the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT). Oral presentation at the ASBMR 2016 Annual Meeting, Atlanta, GA, September 16-19, 2016 2016
• Evans D, Alliston T, Zhang B, Youngren J, Recker R, Lappe J, Reppe S, Lang T. Gentic Risk of Hip Fracture Due to Bone Quality Defict. Poster presented at the ASBMR 2016 Annual Meeting, Atlanta, GA, September 16-19, 2016 2016
• Cohen A, Kamanda-Kosseh M, McMahon D, Dempster D, Zhou H, Lappe J, Recker R, Stubby J, Bucovsky M, Shane E. Biopsy-based bone remodeling characteristics of premenopausal women with idiopathic osteoporosis on selective serotonin reuptake inhibitors (SSRIs). Poster presented at the ASBMR 2016 Annual Meeting, Atlanta, GA, September 16-19, 2016 2016
• Akhter M, Hugenroth B, Recker R. Lacunar Void Properties in Bone Tissue from Women Treated with Alendronate. Poster presented at the ASBMR 2016 Annual Meeting, Atlanta, GA, September 16-19, 2016 2016
• Rizzo A, Farlay D, Akhter M, Boskey A, Recker R, Lappe J, Boivin G. Variables Reflecting the Mineralization of Bone Tissue from Fracturing versus Non-fracturing Postmenopausal Women. Poster presented at the ASBMR 2016 Annual Meeting, Atlanta, GA, September 16-19, 2016 2016
• Recker, R. Nanno-Indentation and FTIRI in Bone Quality. Osteoporosis Research Center Friday Conference. Creighton University Medical Center, February 5, 2016. 2016
• Recker R. State-of-the-art in histomorphometry, including selected aspects of innovations in osteoporosis treatment. Presented at the Annual Autumn conference of the Austrian Society for Bone and Mineral Research, December 4, 2015. 2015
• Recker R. Osteoporosis medications. Presented at Creighton University osteoporosis Research Center Bone health Group, Wednesday, November 11, 2015 2015
• Recker R. Osteoporosis Research Center. Health Sciences Library Staff Development Session, Wednesday, November 11, 2015. 2015
• Recker R. Osteoporosis. Presented at Creighton university medical Center Division of osteoporosis/Endocrinology, Grand Rounds Conference, October 20, 2015. 2015
• Cohen A, Manavalan J, Kousteni S, Recker R, Lappe J, Dempster D, Zhou H, McMahon D, Bucovsky M, Kamanda-Kosseh M, Stubby J, Shane E. Circulating osteogenic progenitors (COPs) and COP surface IGF-1 receptor density predict tissue-based bone formation rate and response to teriparatide (TPTD) in premenopausal women with idiopathic osteoporosis (IOP). ASBMR 2015 Annual Meeting, Seattle, WA, October 9-12, 2015. 2015
• Vennin S, Desyatova A, Turner J, Recker R, Akhter M. Intrinsic material property differences in bone tissue from fracturing vs non-fracturing women. ASBMR 2015 Annual Meeting, Seattle, WA, October 9-12, 2015. 2015
• Boskey A, Spevak L, Boskey ER, Recker RR. Age Matters: Correlating Age with Spectroscopic Markers of Fragility Risk. ASBMR 2015 Annual Meeting, Seattle, WA, October 9-12, 2015. 2015
• Dempster D, Zhou H, Recker R, Brown J, Recknor C, Lewiecki E, Miller P, Rao S, Kendler D, Drege J, Alam J, Taylor K, Janos B, Ruff, V. Anabolism Versus Antiresorption (AVA Study): A comparison of the mechanism of action (MOA) of Teriparatide (TPTD) and Denosumab (DMAb) in Postmenopausal Women with Osteoporosis using quadruple fluorochrome labeled bone histomorphometry. ASBMR 2015 Annual Meeting, Seattle, WA, October 9-12, 2015. 2015
• Cohen A, Kamanda-Kosseh M, Zhou H, Dempster D, Bucovsky M, Stubby J, Recker R, Lappe J, Shane E. Pregnancy and lactation associated osteoporosis (PLO): Similar bone structure and lower bone remodeling than idiopathic osteoporosis. ASBMR 2015 Annual Meeting, Seattle, WA, October 9-12, 2015. 2015
• Cleland T, Cohen A, Dempster D, Recker R, Lappe J, Zhou H, Shane E, Vashishth D. Advanced Glycation End-products are Higher in Trabecular Bone from Premenopausal Women with Idiopathic Osteoporosis. ASBMR 2015 Annual Meeting, Seattle, WA, October 9-12, 2015. 2015
• Binkley N, Lappe J, Davies K, Recker R. Vitamin D Status and Bone Mineralization: A Histomorphometric Analysis. Accepted for oral presentation. ASBMR 2015 Annual Meeting, Seattle, WA, October 9-12, 2015. 2015
• Joven MH, Armas LAG, Whyte MP, Recker RR, Mumm S. Adult Hypophosphatasia Presenting with a Low Bone Remodeling Rate. Accepted for presentation at the AACE Annual Meeting, Nashville, TN May 14-15, 2015. 2015
• Paschalis EP, Gamsjaeger S, Hassler N, Brozek W, Fratzl P, Eriksen EF, Rauch F, Glorieux FH, Shane E, Dempster D, Recker R, Klaushofer K. Aging vs postmenopausal osteoporosis: Turnover-independent bone composition maturation kinetics at actively forming trabecular surfaces. Submitted for presentation at the European Calcified Tissue Society (ECTS) and the International Bone and Mineral Society (IBMS), Rotterdam, The Netherlands, April 25-28, 2015. 2015
• Cohen A, Manavalan S, Kousteni S, Recker R, Lappe J, Dempster D, McMahon D, Bucovsky M, Kamanda-Kosseh M, Stubby J, Shane E. Circulating osteoblast progenitors and IGF-1 receptor density on these cells correlate with bone formation on transiliac biopsies and predict response to teriparatide in premenopausal women with idiopathic osteoporosis. Accepted for poster presentation at the Endocrines Society Annual Meeting, San Diego, CA, March 5-8, 2015. 2015
• Cohen A, Dempster D, Zhou H, Recker R, Lappe J, Cremers S, Muller R, Zwahlen A, Kamanda-Kosseh M, Bucovsky M, Stein E, Nickolas T, Shane E. Healthy premenopausal women with low HDL (less than 50 mg/dL) have significantly lower trabecular bone volume and bone formation rate. Accepted for poster presentation at the Endocrines Society Annual Meeting, San Diego, CA, March 5-8, 2015. 2015
• Cohen A, Manavalan S, Kousteni S, Recker R, Lappe J, Dempster D, McMahon D, Bucovsky M, Kamanda-Koseh M, Stubby J, Shane E. Early increase in IGF-1 receptor density on circulating osteogenic progenitor cells predict responsiveness to teriparatide. ASMBR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Boskey A, Spevak L, Watson P, Bare S, Recker R. Tissue heterogeneity determined by FTIR imaging decreases with increasing fracture count. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Benson C, Chiang A, Hu L, Jahangir A, Mitlak B, Recker R, Robins D, Sowa H, Sipos A. Effects of 2 years of treatment with romosozumab followed by 1 year of denosumab or placebo in postmenopausal women with low bone mineral density. ASBMR 2014 Annual Meeting, Houston TX September 2014. 2014
• Rosauer B, Akhter M, Kimmel D, Lappe J, Recker R. Osteocyte lacunar density is breed related in mice. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Armas L, Recker R. Type 1 diabetes mellitus effects on bone: results of histomorphometric analysis. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Recker R, Dempster D, de VilliersT, langdahl B, Miller P, Valter I, Zerbini C, Cohn D, Doleckyj S, Duong L, Scott B, Verbruggen N, Santora A. Effects of odanacatib on bone structure and quality in postmenopausal women with osteoporosis: Results from the phase III long-term odanacatib fracture trial (LOFT). ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Akhter M, Cullen D, Danforth J, Alvarez G, Hackfort B, Recker R. Biomechanical analyses of bone tissue damage from fatigue loading in vivo. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Cohen A, Manavalan JS, Recker R, Lappe L, Dempster D, McMahon DJ, Kousteni S, Bucovsky M, Kamanda-Kosseh M, Stubby J, Shane E. Early increases in circulating osteogenic progenitor (COP) cells and COP cell surface IGF-1 receptor density in response to teriparatide. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Carballido-Gamio J, Bonaretti S, Saeed I, Harnish R, Recker R, Burghardt A, Keyak J, Harris T, Sundeep K, Lang T. Automatic QCT quantification of the proximal femur: vBMD, bone volume, cortical bone thickness and finite element modeling. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Cohen A, Kamanda-Kosseh M, Recker R, Lappe J, Dempster D, Zhou H, Cremers S, Bucovsky M, Stubby J, Shane E. Characteristics of premenopausal women with idiopathic osteoporosis who experience significant bone loss after teriparatide cessation. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Tribble MB, Cohen A, deBakker C, Lappe J, Recker R, Nishiyama K, Rubin M, Bilezikian J, Shane E, Liu XS. Increased endocortical formation and periosteal resorption at the distal tibia in premenopausal women with idiopathic osteoporosis treated with 18 months of teriparatide. ASBMR 2014 Annual Meeting, Houston TX September 2014. 2014
• Farlay D, Armas L, Gineyts E, Recker R, Boivin G. Pentosidine and degree of mineralization are increased in bone from fractured-patients with type 1 diabetes mellitus. ASBMR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Gamsijaeger S, Brozek W, Recker R, Klaushofer K, Paschalis,EP. Transmenopausal changes in cortical bone quality. ASMBR 2014 Annual Meeting, Houston, TX September 2014. 2014
• Cullen D, Akhter M, Danforth J, Alvarez G, Hackfort B, Recker R. Inflammatory signals associated with in vivo fatigue damage. ORS 60th Annual Meeting, New Orleans, LA, March 2014. 2014
• Tarasova V, Nahar N, Dietz N, Recker R, Anderson R. Unique occurrence and course of Graves in a patient with PTEN hamartoma tumor syndrome. ATA 83rd Annual Meeting, Puerto Rico. Thyroid 23(1): 177 Oct. 2013. 2013
• Dempster D, Zhou H, Recker R, Brown J, Bolognese M, Recknor C, Kendler D, Lewiecki EM, Rao S, Miller P, Woodson G, Lindsay R, Binkley N, Alam J, Ruff V, Janos B, Taylor K. A longitudinal study of skeletal Histomorphometry in subjects on Teriparatide (TPTD) or Zoledronic acid (ZOL), the SHOTZ study. ASBMR 35th Annual Meeting, Baltimore, MD 2013. 2013
• Nishiyama K, Wang J, Young P, Recker R, Lappe J, Cremers S, Guo X, Shane E, Cohen A. Teriparatide is associated with improved microarchitecture and estimated bone strength in premenopausal women with idiopathic osteoporosis: An HR-pQCT study. ASBMR 35th Annual Meeting, Baltimore, MD 2013. 2013
• Akhter M, Danforth J, Kimmel D, McElwee J, Furia M, Pennypacker B, Duong LT, Recker R, Opiteck G. Bone structure and strength in three mouse crosses as a function of strain. ASBMR 35th Annual Meeting, Baltimore, MD 2013. 2013
• Kepley A, Shen W, Mayer L, Shane E, Weigel J, Kenney L, Young P, Zhang C, Recker R, Lappe J, Cohen A. Premenopausal women with idiopathic osteoporosis and those with anorexia nervosa have similar bone structural defects but differ in terms of marrow fat. ASBMR 35th Annual Meeting, Baltimore, MD 2013 2013
• Farlay D, Armas L, Martin A-S, Recker R, Boivin G. Bone material properties are impaired in fractured -patients with type 1 diabetes mellitus. ASBMR 35th Annual Meeting, Baltimore, MD 2013. 2013
• Cohen A, Costa A, Recker R, Lappe J, Cremers S, Dempster D, Zhou H, Zwahlen A, Miller R, Stein E, Nickolas T, Rosen C, Shane E. Lower bone volume fraction and bone formation rate in premenopausal women with abdominal obesity are associated with less physical activity and higher serum sclerostin. ASBMR 35th Annual Meeting, Baltimore, MD 2013. 2013
• Boskey A, Spevak L, Mandair G, Bare S, Recker R, Morris M. Correlating FTIRI and raman parameters using iliac crest biopsies. ASBMR 35th Annual Meeting, Baltimore, MD 2013 2013
• Novel therapies for osteoporosis: Sun Valley Workshop, Sun Valley ID. 2005
• A 5 year randomized trial of the long-term efficacy and safety of alendronate: the Fit Long-term EXtension (FLEX): Merck, Chicago IL. 2005
• Clinical review of the FLEX data: Merck, Chicago IL. 2005
• How do anti-resptive agents prevent fractures with so little increase in BMD? CME, Omaha NE. 2005
• What's new in vitamin D? CME, Omaha NE. 2005
• Controversies in bone and mineral metabolism To D or not to D - That is the question!: NKF, Washington DC. 2005
• Bone quality: What is it and can we measure it? NIH Bone Quality, Washington DC. 2005
• Current trends of osteoporosis: AMCP, Denver CO. 2005
• Efficacy of monthly BNIVA (ibandronate sodium) tablets: GSK, Dallas TX. 2005
• Current concepts in the prevention and treatment of osteoporosis: UMKC, Kansas City MO. 2005
• Bone remodeling and the BMD paradigm: NOF, Washington DC. 2005
• Genetic research in osteoporosis: Where are we? Where should we go next? P&G, Cincinnati OH. 2005
• Current concepts in the prevention and treatment of osteoporosis: University of Cincinnati, Cincinnati OH. 2005
• Current management of osteoporosis: Roche, Las Vegas NV. 2005
• Therapeutic agents: GSK-Roche, Raleigh NC. 2004
• Diagnostic and public health considerations in osteoporosis: GSK-Roche, Raleigh NC. 2004
• Permissible exposure limit (PEL) for bone: NASA, Houston TX. 2004
• Cancellous bone formation and structure: a bone biopsy study: Grand Rounds, Omaha NE. 2004
• Bone quality and fracture risk: ACR, San Antonio TX. 2004
• Investigational uses of ibandronate in treatment of osteoporosis: WONCA, Orlando FL 2004
• Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. ASBMR - Seattle, WA. 2004
• Update of bone quality research and its current and future clinical application. ASBMR - Seattle, WA. 2004
• Calcium absorption: techniques and interpretation. ASBMR - Seattle, WA. 2004
• Current and new therapies in osteoporosis: ASBMR, Seattle WA. 2004
• New therapies in osteoporosis. ASBMR - Seattle, WA. 2004
• Bone microarchitecture after 10 years of alendronate treatment: the FLEX study, ASBMR, Seattle WA. 2004
• How do you obtain transilial bone biopsies: What information can you learn from them? Grand Rounds, Novartis, Newark NJ. 2004
• Genetic research in osteoporosis: Where are we? Where should we go next? Merck, Philadelphia. 2004
• Osteoporosis in Family Practice: Current concepts in the prevention and treatment of osteoporosis: Morrison Seminar Room. 2004
• Osteoporosis in Family Practice: Current concepts in the prevention and treatment of osteoporosis, Lincoln, NE. 2004
• Genetic Research in osteoporosis: Where are we? Where should we go next?: Endocrine Research Conference, New York. 2004
• Genetic Research in osteoporosis: Where are we? Where should we go next?: Metropolitan Bone Club, New York. 2004
• How does bone turnover explain fracture risk?: Bone Rounds, Columbia University. 2004
• Osteoporosis: Updated to 2004: Prevention and treatment of osteoporosis, Columbia University. 2004
• Milk-Alkali syndrome due to tums: BRC01 CME program. 2004
• Current concepts in the prevention and treatment of osteoporosis: Grand Rounds, Department of Orthopaedic Surgery, UNMC 2004
• The clinical trials of ibandronate results: BRC01 CME program. 2004
• Activation frequency, what is it telling us?: BRC01 CME program. 2004
• Ostoeporosis: Updated to 2003: Nebraska Academy of Family Practice, Lincoln, NE. 2003
• Genetic Research in Osteoporosis: State of the Art-2003: Massey Lecture, University of North Dakota. 2003
• Protecting bone & minimizing fracture risk after age 40: Nutritional perspective, University of North Dakota. 2003
• Daily and intermittent oral ibandronate : an evaluation of bone histomorphometry in postmenopausal osteoporosis. ACR/ARHP Annual Scientific Meeting, Orlando, Florida, 2003. 2003
• Genetic Research in Osteoporosis: Where are we? Where should we go next?: Internation Conference on Osteoporosis and Bone Research, Beijing, China. 2003
• Bone biology fundamentals; modeling and remodeling; Pittsburgh Bone Symposium, Pittsburgh, PA. 2003
• Bone Quality and Fracture Protection with Risedronate: ASBMR, August 2003. 2003
• Transmenopausal and age-related changes in bone remodeling: activation frequency in transilial bone biopsies; Proctor & Gamble, Cincinnati, OH. 2003
• Transmenopausal and age-related changes in bone remodeling: activation frequency in transilial bone biopsies; Sun Valley Hard Tissue Workshop, Sun Valley, ID. 2003
• Endocrine Society 85th Annual, Philadelphia PA 2003
• Mary Greeley Medical Center, Ames IA 2003
• Novartis/Zoledronic Acid Advisory Board, Phoenix AZ 2003
• Novartis Roundtable, Phoenix AZ 2003
• National Institutes of Health (NIH) Grand Rounds, Bethesda MD 2002
• Endocrine Grand Rounds (Harvard), Boston MA 2002
• CME, Country Club, Lincoln, NE 2002
• National Advisory Board for Osteoporosis (Lilly), Chicago IL 2002
• P & G, Cincinnati OH 2002
• University of New Mexico, Albuquerque NM 2002
• Women's Health Conference, Omaha NE 2002
• Orthopaedic Forum, Council Bluffs IA 2002
• ASBMR Annual Meeting, San Antonio, TX; September 2002. 2002
• ASBMR Annual meeting, San Antonio TX 2002
• Merck External Advisory Board, Philadelphia PA 2002
• Sun Valley Workshop, Sun Valley ID 2002
• University of Oklahoma, Oklahoma City OK 2002
• Site Visit, Bethesda MD 2002
• ASBMR Summer Council, June 26-28, 2002, Washington, DC 2002
• World Congress on Osteoporosis, May 10-14, 2002, Lisbon, Portugal 2002
• NIAMS Coalition Day, April 16-17, 2002, Washington, DC 2002
• ASBMR Winter Council, January 25-26, 2002, Washington, DC 2002
• NIAMS Coalition Day, January 9, 2002, Washington, DC 2002
• Topic TBA, November 27-29, 2001, NJ 2001
• ASBMR Management Seminar, November 19-20, 2001, Washington, DC (Tyson's Corner) 2001
• National Scientific Osteoporosis Advisory Board, November 16-18, 2001, San Francisco, CA 2001
• Skeletal Genetics: The Next Decade, October 29-31, 2001, National Institutes of Health, Washington, DC 2001
• Genetic Regulation of Bone Mass and Risk of Fractures, VIII Spanish Bone and Mineral Society, October 20-27, 2001, Menorca, Spain 2001
• Presentation of Abstract: The Effect of Alendronate and Estrogen Replacement on Periosteal Bone Formation, ASBMR Annual Meeting, October 16, 2001, Phoenix, AZ 2001
• Special Session for Allied Health Professionals--High Bone Mass, ASBMR Annual Meeting, October 13, 2001, Phoenix, AZ 2001
• The Genetics of Osteoporosis, ASBMR Annual Meeting, October 13, 2001, Phoenix, AZ 2001
• Faculty Slide Review, ASBMR, October 12, 2001, Phoenix, AZ 2001
• ASBMR Press Conference, October 12, 2001, Phoenix Civic Plaza, Phoenix, AZ 2001
• Protecting Bone Health with Lower Hormone Replacement Therapy Doses, ASBMR Annual Meeting, October 12, 2001, Phoenix, AZ 2001
• American Society for Bone and Mineral Research Annual Meeting, October 10-16, 2001, Phoenix, AZ, President Elect 2001
• Bone Biopsy Processing, September 29-30, 2001, San Francisco, CA 2001
• Bone Biopsy Processing, September 15-16, 2001, Orlando, FL 2001
• Exercise Kids Study, September 10-11, 2001, Bethesda, MD 2001
• Ibandronate Clinical Update Meetings, September 7-8, 2001, San Diego, CA 2001
• Ibandronate Clinical Update Meetings, August 30-September 2, 2001, Geneva, Switzerland 2001
• 31st International Sun Valley Hard Tissue Workshop Co-Organizer, August 6-10, 2001 Osteoporosis Workshop, Sun Valley, ID, August 10, 2001 2001

Awards

• O’Brien Endowed Chair in Health Sciences Award
  Creighton University
• Crystal Caduceus Award
  Creighton University Medical Alumni Advisory Board
• Federic C. Bartter Award, ASBMR, September 2003